Chemotherapy in the Management of Prostate Cancer

Less than a decade ago, metastatic castration-resistant prostate cancermetastatic castration resistant prostate cancer (mCRPC) was deemed to be a “chemoresistant” disease, with a poor prognosis. The landmark TAX327TAX327 trial trial, published in 2004, showed that a course of chemotherapy based on t...

Full description

Saved in:
Bibliographic Details
Published inPrinciples and Practice of Urooncology pp. 351 - 365
Main Author Bavbek, Sevil
Format Book Chapter
LanguageEnglish
Published Switzerland Springer International Publishing AG 2017
Springer International Publishing
Subjects
Cabazitaxel
Chemotherapy
Docetaxel
Metastatic castration-resistant prostate cancer
Oncology
Radiotherapy
Urology & urogenital medicine
Online AccessGet full text

Cover

More Information
Summary:Less than a decade ago, metastatic castration-resistant prostate cancermetastatic castration resistant prostate cancer (mCRPC) was deemed to be a “chemoresistant” disease, with a poor prognosis. The landmark TAX327TAX327 trial trial, published in 2004, showed that a course of chemotherapy based on the taxane docetaxel could extend survival for men with mCRPC. Then, in 2010 it was reported that men with mCRPC who progressed during or after docetaxel could gain a further survival benefit from a second line of chemotherapy, based on another taxane, cabazitaxel.
ISBN:9783319561134
3319561138
DOI:10.1007/978-3-319-56114-1_21